Showing results (1-10 of 622) with videos related to
Sort By:
Pageof 63
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 2022
Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and LimitationsOliver Sartor, Ken HerrmannEuropean Urology|April 16, 2026
Considerations for Earlier Use of Radiopharmaceutical Therapy in Prostate CancerMarc B Garnick, Ken Herrmann, PET Clinics|July 18, 2014
Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfallsKen Herrmann, Andreas K BuckPET Clinics|May 10, 2016
Therapy Monitoring with Fluorine-18 FDG-PET and Fluorine-18 FDG-PET/CTHinrich A Wieder, Ken HerrmannJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2019
Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression CriteriaStefano Fanti, Boris Hadaschik, Ken HerrmannMed (New York, N.Y.)|April 18, 2025
CD70-targeted cancer theranostics: Progress and challengesWeijun Wei, Viktor Grünwald, Ken HerrmannJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 10, 2014
Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 PatientsJohannes Czernin, Lisa Ta, Ken HerrmannJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 9, 2016
18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 PatientsClaudio Spick, Ken Herrmann, Johannes CzerninJournal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2016
Evaluation of Prostate Cancer with 11C-Acetate PET/CTClaudio Spick, Ken Herrmann, Johannes CzerninCancers|December 10, 2021
In Vivo Targeting of CXCR4-New HorizonsMargret Schottelius, Ken Herrmann, Constantin LapaPageof 63